Myocardial Protection in Cardiac Surgery: Del Nido versus Blood Cardioplegia

Abstract

**Objectives:** del Nido cardioplegia which was traditionally used for myocardial protection in pediatric congenital heart surgery is now being extensively utilized in adult cardiac surgery. The aim of this study was to compare the safety and efficacy of del Nido cardioplegia (DNC) with blood cardioplegia (BC). **Materials and Methods:** This is a historical cohort study using secondary data. Two hundred and eighty six patients who underwent coronary artery bypass graft (CABG) or valve surgery were included. They were divided into 2 matched cohorts of which 143 patients received BC and 143 patients received DNC. **Results:** There was no difference in cardiopulmonary bypass time \((P = 0.516)\) and clamp time \((P = 0.650)\) between the groups. The redosing of cardioplegia was significantly less for DNC \((1.13 \text{ vs. } 2.35, P < 0.001)\). The post bypass hemoglobin was higher for DNC \((9.1 \text{ vs. } 8.7, P = 0.011)\). The intraoperative and postoperative blood transfusion was comparable \((P = 0.344)\) \((P = 0.40)\). The incidence of clamp release ventricular fibrillation \((P = 0.207)\) was similar. The creatine kinase-MB isotype levels for the CABG patients were comparable on all 3 days \((P = 0.104), (P = 0.106), \text{and } (P = 0.158)\). The postoperative left ventricle ejection fraction was lesser but within normal range in the DNC group \((53.4 \text{ vs. } 56.0, P < 0.001)\). The duration of ventilation \((P = 0.186)\), ICU days \((P = 0.931)\), and postoperative complications \((P = 0.354)\) were comparable. There was no 30-day mortality or postoperative myocardial infarction in both the groups. **Conclusion:** DNC provides equivalent myocardial protection, efficacy, and surgical workflow and had comparable clinical outcomes to that of BC. This study shows that DNC is a safe alternate to BC in CABG and valve surgeries.

**Keywords:** Blood cardioplegia, Del Nido, efficacy, myocardial protection

Introduction

Adequate myocardial protection is essential for a successful clinical outcome during cardiac surgery. The main principles of myocardial protection are reduction of metabolic activity by hypothermia and diastolic arrest of the electrical activity of the heart by administering cardioplegia.\(^1\) This provides the surgical team with a still, bloodless field essential for their surgical precision.

There is no clear consensus on the optimal composition of cardioplegic solutions.\(^2\) The composition varies based on institutional preferences. The two main types that have gained widespread acceptance are diastolic arrest induced and maintained with potassium added to either blood-based solution or a crystalloid-based solution.\(^1,3\) There are several types of blood cardioplegia that differ in their electrolyte and drug additives which are supplemented to stabilize the membrane potential. Some examples are Buckberg solution, Plegisol solution, and St. Thomas solution.\(^4\) Del Nido is a crystalloid-based cardioplegia known to have a prolonged arrest time due to the lignocaine and magnesium additive but can inherently cause hemodilution.\(^5\) Although originally designed for a child’s immature heart,\(^6\) del Nido is now used as a new alternative to protect the adult ischemic myocardium in a wide range of surgeries.\(^7\)

In our institution, modified St. Thomas blood cardioplegia (BC) has been the standard solution for cardiac arrest in adult cardiac surgery. We transitioned to del Nido crystalloid cardioplegia (DNC) from May 2017. The purpose of our study was to compare the efficacy and safety of del Nido with the conventional blood cardioplegia in different cardiac surgical groups.
Materials and Methods

Our institution is a tertiary care center where all our patient data is stored in an easily retrievable form. The study design is a historical cohort using secondary data from January 2017 to August 2017 inclusive of the period of transition. The Institutional Ethics Committee approved the study (IRB no. 10998). The requirement for informed consent from individual patients was waived because of the study design. We extracted all patient information and clinical data from perfusion charts, anaesthesia records, postoperative intensive care unit (ICU) charts, and the in-house hospital information system. A sample size of 122 (61 in each group) was calculated based on the study by Mishra et al.\(^8\) to test the mean difference of 21 and with standard deviation of 42 for the time duration of cardiopulmonary bypass (CPB) with 80% power and at 5% level of significance. Given that we are using secondary data, we took a larger number of cases. Two hundred and eighty six patients were included in the study. They were divided into 2 matched cohorts of which 143 patients received BC and 143 patients received DNC.

We included all adult patients from age group of 18 to 80 years who underwent elective cardiac surgery under CPB requiring cross-clamping of the aorta and the administration of cardioplegia. The surgeries included were coronary artery bypass grafting (CABG), aortic (AVR) and mitral (MVR) valve replacement, double valve replacement (DVR), mitral valve replacement with tricuspid annuloplasty (MVR + TAP), and double valve replacement with tricuspid annuloplasty (DVR + TAP). We excluded pediatric and adult congenital cardiac surgeries, CABG with valve surgeries, arch surgeries, and redo and emergent surgeries.

We analyzed three categories of variables in each group: Patient demographics, intraoperative variables, and postoperative variables. In order to assess the efficacy, we compared the aortic cross clamp (ACC) times and CPB times and the number of doses of cardioplegia required. In addition, we looked at intraoperative hemoglobin (Hb) values to observe if there was an increased risk of blood transfusion with DNC. The safety was evaluated by analyzing the adequacy of myocardial protection and presence of postoperative myocardial injury. This was done by assessing the incidence of ventricular tachyarrhythmias or fibrillation (VT/VF) necessitating electrical defibrillation post ACC removal. We also compared creatine kinase-MB isotype (CK-MB) in CABG patients and left ventricular (LV) function for all patients by transthoracic echocardiography (TTE) done on fifth postoperative day. Moreover, we looked into frequency and duration of temporary pacing in each group. Postoperative clinical outcome variables like incidence of new arrhythmia, myocardial infarction (MI), ICU stay, hospital stay, and postoperative complications were also looked at.

All patients selected for the study were operated within a period of 8 months and, therefore, the effect of changes and advances in surgical care in this short interval can be considered minimal and the standardized protocols in our center were not altered. Because of the study design, we attempted to minimize inherent selection bias by including consecutive patients and equal number of patients in each surgical group. Patients were operated by the same set of surgeons. All patients were given a standard general anesthesia protocol employing CPB with mild systemic hypothermia (30°C to 34°C). Myocardial protection consisted of administration of one of these cardioplectic solutions through antegrade route along with topical slushed ice.

Cardioplegia preparation and administration [Table 1]

**Modified St. Thomas blood cardioplegia**

The BC solution is given as two doses: Induction dose and maintenance dose. Induction dose was prepared by adding 2 ampoules of St. Thomas cardioplegia concentrate to 500 ml Ringers Lactate (RL). St Thomas concentrate solution contains procaine hydrochloride, potassium chloride (KCL), and magnesium chloride. It was modified by adding extra KCL and 8.4% sodium bicarbonate (NaHCO₃). Maintenance dose was made by adding 1 ampoule of the cardioplegia concentrate to 500 ml RL with additional 8.4% NaHCO₃. The BC was given in a 4:1 ratio of patient’s blood to crystalloid (cardioplegia). The arresting dose was 20 ml/kg and a redose of 10 ml/kg was given every 20–25 min.

**Del Nido cardioplegia**

The DNC solution was prepared in 1000 ml of Plasma-Lyte A to which KCl, 8.4% NaHCO₃, 20% mannitol, 50% magnesium sulphate, and 2% lignocaine were added. The final composition is given in the ratio of 1:4 patient’s blood to crystalloid (cardioplegia). The initial arresting dose is 20 ml/kg up to a maximum of 1200 ml. A redose of 10 ml/kg was given at 60 min if the anticipated duration of ischemia is more than 90 min.

The DNC solution was cooled to 4°C–6°C and BC to 8°C–10°C and administered at 300–350 cc/min. Hb was maintained at 7–8 gm% during CPB. Retrograde autologous priming (RAP) and venous antegrade priming (VAP) was done in the patients who were hemodynamically stable. The volume removed varied with each patient. All the blood volume in the CPB circuit was reinfused prior to removal of the aortic cannula. We did not use cell salvage. Pump flows were maintained at 2.2 to 2.4 L/min/m² (based on height, weight, and body surface area) and mean arterial pressure targeted between 50 and 70 mmHg. After surgery, patients were transferred to the ICU and provided standardized postoperative care. Patients were shifted to step down ICU after extubation and weaning from inotropic supports.
Arterial blood gas (ABG) analysis was done at different points in the surgery. All A samples were baseline and taken before anesthesia induction, B samples were during CPB 10–15 min after giving cardioplegia, B samples were 5–10 min after ACC release, and C samples were after protamine administration. In the ICU, all blood samples were taken on arrival. Serial ABGs were subsequently done every 6 h. CK-MB and creatinine were done daily.

If VT/VF occurred after the aorta was unclamped, intravenous lignocaine was given and if the arrhythmia persisted, electrical cardioversion (20–30 joules) was administered with internal paddles. New-onset postoperative atrial fibrillation (AF) was defined as AF occurring in a patient with no history of AF. Postoperative myocardial injury was assessed by CK-MB. We do not check CK-MB preoperatively for elective cases. This is routinely done postoperatively only for the CABG patients. The normal CK–MB range is 5 to 25 IU/L. Values above 40 IU/L were considered to be significant.[9] Perioperative myocardial infarction (MI) was diagnosed with CK-MB above 40 IU/L, ST elevation or appearance of a new Q wave on the electrocardiogram.[9]

Statistical methods

Statistical analysis was performed with STATA version 15.0 (College Station, Texas 77845 USA). Continuous data with normally distributed and skewed variables were reported as mean (SD) and median (IQR) values, with categorical data as frequency and percentages. Differences between categorical variables were tested with the $\chi^2$ test to compare the proportions, and comparison of means was carried out using Student’s t-test for normally distributed and log-transformed data for skewed variables and compared using t-test. Differences were considered significant at values of $P < 0.05$.

Results

A total of 286 patients were included in the analysis with 143 in each group. In each side, 45 had CABG, 34 had AVR, 27 had MVR, 28 had DVR, 5 had MVR + TAP, and 4 had DVR + TAP. Both the groups were similar in their preoperative characteristics including age, gender, ejection fraction (EF), and cardiac risk factors. The median EF was >55% for both groups [Table 2].

There was no difference in CPB time (90 vs. 87, $P = 0.516$) and ACC time (59 vs. 57, $P = 0.650$) between the groups [Table 3]. A subanalysis comparing individual surgeries between the groups [Table 4] also did not show a significant difference between CPB time and ACC time. The number of doses of cardioplegia given was significantly less for DNC (1.13 vs. 2.35, $P < 0.001$).

The Hb values in the A (13.2 vs. 12.9, $P = 0.234$), B (8.0 vs. 7.9, $P = 0.280$), and B1 (8.5 vs. 8.5, $P = 0.101$) samples were comparable but in the C sample (9.1 vs. 8.7, $P = 0.011$), the Hb was significantly higher in the DNC group. Considerably more amount RAP and VAP was done in the DNC group (450 vs. 250 $P = <0.001$). The intraoperative transfusion of blood and blood products was not significantly different between the groups (75 vs. 67, $P = 0.344$).

The incidence of ACC release ventricular VT/VF was comparable in both the groups (21 vs. 14, $P = 0.207$). Less number of patients who developed VF/VT needed defibrillation in the DNC group (10/21 vs. 12/14) and settled with just lignocaine bolus (11/21 vs. 2/14). Fewer patients in the DNC group required pacing on coming off bypass (15 vs. 20, $P = 0.367$) and were paced for significantly less time (2 vs. 4, $P = 0.023$) [Table 3].

The Hb in the ICU at 6 h (10.2 vs. 9.9 $P = 0.14$) and at 24 h (9.6 vs. 9.3 $P = 0.13$) was comparable and the need for postoperative transfusion of blood and products (30 vs. 36, $P = 0.40$) did not differ between the groups [Table 5].

The CKMB levels for the CABG patients in both the groups were comparable on all 3 days (16.9 vs. 20.4, $P = 0.104$), (14.8 vs. 13.0, $P = 0.106$), and (7.0 vs. 6.1, $P = 0.158$). The postoperative TTE showed that the LVEF was lesser but within normal range in the DNC group (53.4 vs. 56.0, $P = <0.001$).

While looking at postoperative clinical outcomes, the incidence of new-onset AF was similar between both the groups (11 vs. 9, $P = 0.643$). The duration of ventilation (16.5 vs. 17.2, $P = 0.186$), ICU days (3.1 vs. 3.1, $P = 0.931$),

| Composition                      | Blood cardioplegia (mST) Induction dose | Blood cardioplegia (mST) Maintenance dose | del Nido |
|----------------------------------|----------------------------------------|------------------------------------------|----------|
| Carrier solution                 | Ringer lactate (500 ml)                | Ringer lactate (500 ml)                  | Plasmalyte (1000) |
| Blood to crystalloid ratio       | 4:1                                    | 4:1                                      | 1:4      |
| Potassium chloride (mEq)         | 36 (32±4)                              | 16                                       | 26       |
| Procaine hydrochloride (1 mmol/20 ml=272 mg) | 544 mg                                | 272 mg                                   | nil      |
| Lignocaine (2%) (mg)             | nil                                    | nil                                      | 130      |
| Magnesium (g)                    | 6.4                                    | 3.2                                      | 2        |
| Sodium bicarbonate 8.4% (mEq)    | 27                                     | 13.5                                     | 13       |
| Mannitol 20% (g)                 | nil                                    | nil                                      | 16       |

mST: Modified St. Thomas

Table 1: Composition of cardioplegia solutions

| Table 2: Results for preoperative characteristics including age, gender, ejection fraction (EF), and cardiac risk factors. The median EF was >55% for both groups.

Table 3: Results for perioperative characteristics including age, gender, ejection fraction (EF), and cardiac risk factors. The median EF was >55% for both groups.

Table 4: Results for intraoperative characteristics including age, gender, ejection fraction (EF), and cardiac risk factors. The median EF was >55% for both groups.

Table 5: Results for postoperative characteristics including age, gender, ejection fraction (EF), and cardiac risk factors. The median EF was >55% for both groups.
### Preoperative characteristics

| Gender | del Nido (n=143) n (%) | Blood cardioplegia (n=143) n (%) | P  |
|--------|------------------------|---------------------------------|----|
| Male   | 100 (69.9)             | 86 (60.1)                       | 0.083 |
| Female | 43 (30.1)              | 57 (39.9)                       |    |
| Age<sup>a</sup> | 48.2 (13.1)       | 46.7 (13.5)                     | 0.337 |
| Ejection Fraction<sup>a</sup> | 57.0 (54.2, 58.8) | 56.5 (54.8, 58.5) | 0.842 |

**Cardiovascular Risk Factors**
- Hypertension: 46 (32.2) vs. 43 (30.1), P=0.702
- Diabetes: 47 (32.9) vs. 45 (31.5), P=0.800
- Smoking: 21 (14.7) vs. 17 (11.9), P=0.486
- COPD: 9 (6.3) vs. 6 (4.2), P=0.426
- Dyslipidemia: 46 (32.2) vs. 45 (31.5), P=0.899
- PAD: 1 (0.7) vs. 0, P=0.316
- Cerebral Vascular Event: 4 (2.8) vs. 6 (4.2), P=0.520
- Arrhythmias: 22 (15.4) vs. 30 (21.0), P=0.220
- Preoperative Hb<sup>b</sup>: 13.2 (1.9) vs. 12.9 (1.7), P=0.157
- Creatinine<sup>b</sup>: 0.88 (0.73, 1.01) vs. 0.86 (0.70, 1.01), P=0.206

Reported with n (%) for categorical variables with Chi-square P. 'Mean (SD) for the continuous normally distributed variables and 'Median (IQR) for continuous skewed variables. Comparison of means was carried out using Student’s t-test for normally distributed and log-transformed data for skewed variables and compared using t-test. P<0.05 is significant. COPD: Chronic obstructive pulmonary disease, PAD: Peripheral arterial disease, Hb: Hemoglobin

### Intraoperative data

| Intraoperative variable | del Nido (n=143) Mean (SD) | Blood cardioplegia (n=143) Mean (SD) | P  |
|-------------------------|-----------------------------|-------------------------------------|----|
| Cardiopulmonary bypass time (min)<sup>b</sup> | 90.0 (74.0, 116.0) | 87.0 (76.0, 108.0) | 0.516 |
| Cross clamp time<sup>c</sup> (min) | 59.0 (48.0, 75.0) | 57.0 (47.0, 70.0) | 0.650 |
| Number of Doses of cardioplegia | 1.13 (0.3) | 2.35 (0.5) | <0.001 |
| Hb a (g/dL) | 13.2 (2.1) | 12.9 (1.8) | 0.234 |
| Hb b (g/dL) | 8.0 (2.0) | 7.9 (2.1) | 0.280 |
| Hb b<sub>1</sub> (g/dL) | 8.5 (1.2) | 8.5 (5.9) | 0.101 |
| Hb c (g/dL) | 9.1 (1.5) | 8.7 (1.0) | 0.011 |
| RAP/VAP<sup>d</sup> | 450 (300, 500) | 250 (0, 300) | <0.001 |
| Blood Products | 75 (52.5) | 67 (46.9) | 0.344 |
| Red Blood Cells<sup>e</sup> | | | 0.716 |
| 1 | 35 (48.6) | 36 (54.6) | |
| 2 | 23 (31.9) | 20 (30.3) | |
| 3 | 13 (18.1) | 10 (15.2) | |
| 4 | 1 (1.4) | 0 | |
| Fresh Frozen Plasma<sup>e</sup> | | | 0.264 |
| 1 | 1 (16.7) | 1 (50.0) | |
| 2 | 1 (16.7) | 1 (50.0) | |
| 3 | 4 (66.7) | 0 | |
| Platelets<sup>e</sup> | | | |
| 3 | 8 (100.0) | 7 (100.0) | |
| VT/VF | 21 (14.7) | 14 (9.8) | 0.207 |
| No. of defibrillations<sup>e</sup> | | | |
| 1 | 8 (80.0) | 9 (75.0) | |
| 2 | 1 (10.0) | 3 (25.0) | 0.388 |
| 3 | 1 (10.0) | 0 | |
| Lignocaine<sup>e</sup> | 21 (100.0) | 13 (92.9) | 0.214 |
| Pacing<sup>e</sup> | 15 (10.5) | 20 (14.0) | 0.367 |
| Number of hours pacing<sup>e</sup> | 2.0 (1.0, 4.0) | 4.0 (1.5, 75.5) | 0.023 |

Reported with Mean (SD) for the continuous normally distributed variables and 'Median (IQR) for continuous skewed variables, 'n (%) for categorical variable with the Chi-square P. Comparison of means was carried out using Student’s t-test for normally distributed and log-transformed data for skewed variables and compared using t-test. P<0.05 is significant. Hb: Hemoglobin; RAP/VAP: Retrograde autologous priming/venous antegrade priming; VT/VF: Ventricular tachyarrhythmia/ventricular fibrillation
postoperative hospital days (7 vs. 7) and 30-day hospital readmission rates (8 vs. 6, \( P = 0.584 \)) were comparable in both the groups. There was no 30-day mortality or postoperative MI in both groups. The incidence of stroke was alike with both groups having one patient. There was no significant difference in creatinine between the groups.

### Table 4: Comparison between CPB Time and ACC time in the different surgeries

| Surgery       | Cardioplegia | CPB time   | \( P \)  | ACC time   | \( P \)  |
|---------------|--------------|------------|---------|------------|---------|
| AVR del Nido  | 75.0 (65.0, 91.0) | 0.427      | 52.5 (45.0, 62.0) | 0.212   |
| BC            | 79.0 (71.0, 88.0) |           | 54.5 (48.0, 68.0) |         |
| MVR del Nido  | 81.0 (72.0, 91.0) | 0.225      | 54.0 (50.0, 60.0) | 0.294   |
| BC            | 77.0 (65.0, 83.0) |           | 50.0 (43.0, 58.0) |         |
| CABG del Nido | 90.0 (77.0, 116.0)| 0.766      | 56.0 (40.0, 67.0) | 0.704   |
| BC            | 91.0 (76.0, 105.0)|           | 50.0 (43.0, 60.0) |         |
| DVR del Nido  | 118.0 (100.0, 137.0)| 0.322     | 91.5 (76.0, 101.0) | 0.203   |
| BC            | 109.5 (102.5, 122.5)|           | 84.5 (77.0, 92.5) |         |
| MVR+TAP del Nido | 106.0 (96.0, 124.0) | 0.468     | 79.0 (76.0, 81.0) | 0.509   |
| BC            | 105.0 (95.0, 111.0)|           | 81.0 (66.0, 82.0) |         |
| DVR + TAP del Nido | 141.0 (127.0, 153.0) | 0.481     | 114.5 (104.0, 122.5) | 0.491   |
| BC            | 130.0 (110.5, 149.0)|           | 105.5 (94.5, 118.0) |         |

Note: Median (IQR) for continuous skewed variables. log-transformed data for skewed variables and compared using \( t \)-test. \( P < 0.05 \) is significant. CPB: Cardiopulmonary bypass time; ACC: Aortic cross clamp time; BC: Blood cardioplegia; AVR: Aortic valve replacement; MVR: Mitral valve replacement; CABG: Coronary artery bypass graft; DVR: Double valve replacement, MVR + TAP: Mitral valve replacement with tricuspid annuloplasty; DVR + TAP: Double valve replacement with tricuspid annuloplasty

### Table 5: Postoperative data

| Postoperative variable | del Nido \((n=143)\) Mean (SD) | Blood cardioplegia \((n=143)\) Mean (SD) | \( P \)  |
|------------------------|-------------------------------|-------------------------------------------|---------|
| Hb ICU 6 h (g/dL)      | 10.2 (1.5)                   | 9.9 (1.4)                                 | 0.140   |
| Hb ICU 24 h (g/dL)     | 9.6 (1.8)                    | 9.3 (1.3)                                 | 0.130   |
| Blood products         | 30 (21.0)                    | 36 (25.2)                                 | 0.400   |
| Red blood cells\(^a\)  |                               |                                           |         |
| 1                      | 18 (66.7)                    | 26 (78.8)                                 |         |
| 2                      | 4 (14.8)                     | 5 (15.2)                                  | 0.261   |
| 3                      | 3 (11.1)                     | 0                                         |         |
| 4                      | 2 (7.4)                      | 2 (6.1)                                   |         |
| Fresh frozen plasma\(^a\) |                             |                                           |         |
| 1                      | 0                            | 1 (50.0)                                  |         |
| 2                      | 1 (100.0)                    | 0                                         | 0.223   |
| 3                      | 0                            | 1 (50.0)                                  |         |
| Platelets\(^d\)        | 7 (100.0)                    | 4 (80.0)                                  | 0.217   |
| CKMB (IU/L) day 1 (CABG)\(^f\) | 16.9 (15.0, 21.8)           | 20.4 (16.0, 26.5)                         | 0.104   |
| CKMB (IU/L) day 2 (CABG)\(^f\) | 14.8 (11.5, 21.7)           | 13.0 (9.6, 19.0)                          | 0.106   |
| CKMB (IU/L) day 3 (CABG)\(^f\) | 7.0 (5.2, 9.2)               | 6.1 (4.2, 9.5)                            | 0.158   |
| PO LV function\(^f\)   | 53.4 (45.1, 57.1)            | 56.0 (51.7, 57.6)                         | <0.001  |
| New-onset AF\(^#\)     | 11 (7.7)                     | 9 (6.3)                                   | 0.643   |
| Ventilation time (h)   | 16.5 (5.1)                   | 17.2 (3.7)                                | 0.186   |
| ICU (days)             | 3.1 (0.8)                    | 3.1 (0.5)                                 | 0.931   |
| 30-day mortality       | -                            | -                                         |         |
| 30-day hospital Readmission | 8 (57.1)                 | 6 (42.9)                                  | 0.584   |
| Myocardial infarction  | -                            | -                                         |         |
| PO complications\(^a\) | 8 (5.6)                      | 12 (8.4)                                  | 0.354   |
| PO hospital days\(^b\) | 7 (6.8)                      | 7 (6.9)                                   | -       |
| Stroke\(^a\)           | 1 (0.7)                      | 1 (0.7)                                   |         |
| Creatinine day1\(^b\)  | 0.9 (0.8, 1.2)               | 1.0 (0.9, 1.2)                            | 0.309   |
| Creatinine day2\(^b\)  | 0.8 (0.7, 1.0)               | 0.9 (0.7, 1.0)                            | 0.713   |

Note: Reported with Mean (SD) for the continuous normally distributed variables and Median (IQR) for continuous skewed variables. \(^a\)n (%) categorical variable with the Chi-square \( P \). Comparison of means was carried out using Student’s \( t \)-test for normally distributed and log-transformed data for skewed variables and compared using \( t \)-test. \( P < 0.05 \) is significant. Hb: Hemoglobin; ICU: Intensive care unit; CKMB: Creatine kinase-MB isotype; PO: Postoperative; LV: Left ventricle; AF: Atrial fibrillation
on both the days \( P = 0.309 \) \( P = 0.713 \). Postoperative complications were lower in the DNC group \( 8 \) vs. \( 12 \), \( P = .354 \), but not statistically significant. There were \( 4 \) patients who required permanent pacemaker (PPM) insertions in the BC group and none in the DNC group.

**Discussion**

The optimal cardioplegia strategy is far from clear despite a substantial amount of literature on the subject. The cardioplegic solution protects the myocardium against ischemia and events during reperfusion.\(^1\) The use of hypothermic and hyperkalemic cardioplegia solutions have evolved to become the clinical standard.\(^1\) The main factors explored were composition (blood versus crystalloid), various substrate enhancement, the route (antegrade, retrograde, or both), the temperature (cold, tepid, or warm), and the redosing intervals.\(^10\) A recent global survey showed that blood cardioplegia was the most commonly used.\(^2\)

The advantages of blood cardioplegia include the benefits of the oncotic properties of blood to prevent cellular edema, superior buffering capacity, rapid arrest in an oxygen-rich environment, intermittent reoxygenation with intermittent washout of metabolites, and improved preservation of high-energy phosphates.\(^3\)

Crystalloid cardioplegia prevents depletion of high-energy substrates and maintains ultrastructural integrity.\(^5\) DNC is plasmalyte solution modified with magnesium and lignocaine which decrease intracellular calcium concentration, myocardial excitability, cellular metabolism, and energy consumption during and after ischemic arrest. DNC preserves intracellular high-energy phosphates. The proposed benefit of DNC is that it provides an arrest period of more than \( 90 \) min which avoids the need for repetitive interruptions during surgery to administer multiple doses as done for standard BC but at the cost of hemodilution.\(^11\) Despite extensive research, the superiority of blood over crystalloid cardioplegia has not been established.\(^5\)

Due to unfamiliarity with DNC, apprehensions have been present about its safety in cardiac surgeries especially in patients with LV dysfunction. Many institutions in India and worldwide are now using DNC in various surgeries but most available studies deal only with isolated surgical groups. Our study looked into its use in all CABG and valve surgeries inclusive of patients with LV dysfunction with EF ranging from \( 28\%–68.6\% \) for DNC and \( 27.7\%–68.1\% \) for BC.

The main additive in DNC was lignocaine, while it was procaine hydrochloride in our BC. Both are Class \( 1 \) sodium channel blockers that directly block the sodium channels in phase 0 depolarization of the action potential.\(^11,12\) Compared with procaine, lignocaine has a longer half-life.\(^12\) This gave DNC group the advantage of longer ischemic times between doses of cardioplegia. The redosing for DNC is significantly less, which allowed the surgeons to do an uninterrupted surgery with better workflow. Our study did not show difference in CPB time and ACC time similar to studies by Guajardo et al.\(^13\) in their study on CABG. Sorabella et al.\(^14\) in their study on redo AVR, Ad et al.\(^15\) in their study on CABG and valves, and Timek et al.\(^16\) in their study in CABG. However, Ota et al.\(^17\) and Mick et al.\(^18\) on their studies on AVR, Kim et al.\(^19\) in their study on various valve surgeries, and Mishra et al.\(^19\) in their study on CABG and DVR found both CPB and ACC time be significantly less with DNC.

The DNC group remarkably had higher Hb throughout and significantly higher post CPB compared to BC. Furthermore, the requirement of blood transfusion both intraoperative and postoperatively was similar to BC group. The most likely reason is significantly more amount of RAP and VAP was done for the DNC group. This was done as protocol in order to counteract the hemodilution with DNC. Hofmann et al.\(^20\) and Teman et al.\(^21\) in their studies demonstrated that transfusion requirements were less and postoperative Hb was higher in the patients where RAP and VAP was done. In addition, since the redosing is substantially less for DNC, the additional cardioplegia volume was not delivered like it was for BC. Mishra et al.\(^19\) and Sorabella et al.\(^14\) had similar findings. Guajardo et al.\(^13\) and Kim et al.\(^19\) surprisingly had a significant reduction in transfusions rates with DNC compared to BC.

In our study, the incidence of post ACC release VT/VF was not statistically significant between the groups. Sadeghi et al.\(^13\) in a study comparing cardioplegia using lignocaine or procaine had similar findings. The study by Sellevold et al.\(^22\) has shown procaine to be a good membrane stabilizer which is effective in minimizing post ischemic VT/VF. Interestingly, the DNC group required less defibrillation compared to BC group, with many settling with a lignocaine bolus. Studies by Guajardo et al.\(^13\) O’Donnell et al.\(^23\) on CABG patients, and Buel et al.\(^24\) on pediatric cardiac patients showed post ACC release defibrillation requirement was significantly less with DNC compared with BC. Guajardo et al.\(^13\) used Buckberg solution which had tromethamine and citrate phosphate, while O’Donnell et al.\(^23\) and Buel et al.\(^24\) used Plegisol which had magnesium and calcium. The lignocaine in DNC can be the component responsible for this outcome.

The postoperative CKMB was comparable in both the groups and did not rise above the normal range on all 3 days. This study did not show increased myocardial injury in the CABG patients receiving DNC compared to BC. Similarly, Timek et al.\(^16\) along with Mick et al.\(^19\) had no difference in enzyme levels. Kim et al.\(^19\) and Vistarini et al.\(^25\) who compared AVR and Hamad et al.\(^26\) who compared valve with CABG found CKMB levels to be significantly lower in DNC, suggesting that blood cardioplegia does not confer superior myocardial protection.
Our study showed a significantly better LV function postoperatively in the BC group. Although it is statistically significant, it is not clinically relevant, because for both groups, it is in normal range of LV function. Our study was inclusive of patients with moderate-to-severe LV dysfunction (6 vs. 5) in each group. None of our patients required intra-aortic balloon pump for weaning off bypass. Studies by Mishra et al.,[9] Timek et al.,[16] Mick et al.,[18] and Yerebackan et al.[27] who looked at high-risk CABG also had preserved LV functions with DNC and did not find BC to be superior to DNC.

We had no differences in postoperative outcomes with relation to duration of ventilation, ICU stay, neurological dysfunction, or renal impairment. None of the patients had postoperative MI or 30-day mortality. Guajardo et al.,[13] O’Donnell et al.,[23] and Hamad et al.,[50] had similar findings. Our comparable findings in relation to incidence of new-onset AF were consistent with studies by Ota et al.,[17] Mick et al.,[18] and O’Donnell et al.[22] Our complication rates did not differ significantly. Multiple other studies[9,14,15,19,25,26] had similar findings.

There was a higher occurrence of conduction defects requiring pacing to wean from bypass and significantly longer duration of pacing in the BC group. There was also an increased incidence of PPM insertion. This corroborates a study by Gundry et al.[39] where they theorized that at very low temperatures, blood undergoes rouleaux formation with potential capillary plugging and this might cause localized ischemia of the conduction system.

### Study limitations

There are a few limitations that must be noted. Since this is a historical cohort study, there can be an inherent selection bias. High-risk patients like those requiring preoperative inotropic support or patients who had acute coronary syndrome have not been included. As this is a single-center study, it may limit the ability to generalize the results. The number of patients enrolled for certain surgeries was relatively small.

### Conclusion

This study which comprised of a diversity of cases inclusive of CABGs and wide range of valve surgeries showed that del Nido cardioplegia provided equivalent myocardial protection and surgical workflow and had clinical outcomes that were similar to that of blood cardioplegia. We feel that the practice of RAP and VAP along with the reduced redosing lessens the hemodilution with del Nido, thus decreasing the transfusion requirements. Del Nido has the safety profile and efficacy comparable to blood cardioplegia. We can conclude that del Nido is a safe alternate to blood cardioplegia in CABG and valve surgeries. Further randomized, multicenter trials comparing different solutions in different cardiac procedures need to be done to validate these results.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### References

1. Gunnes S, Jynge P. Fundamentals of the past: Cardioplegia: The first period revisited. In: Podesser BK, Chambers DJ, editors. New Solutions for the Heart. An Update on Advanced Perioperative Protection. 1st ed. Germany: Springer-Verlag/Wien; 2011. p. 15-40.
2. Ali JM, Miles LF, Abu-Omar Y, Galardo C, Falter F. Global cardioplegia practices: Results from the global cardiopulmonary bypass survey. J Extra Corpor Technol 2018;50:83-93.
3. Zeng J, He W, Qu Z, Tang Y, Zhou Q, Zhang B. Cold blood versus crystalloid cardioplegia for myocardial protection in adult cardiac surgery: A meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2014;28:674-81.
4. Chatrath R, Kaul TK, Walker DR. Myocardial protection during cardioplegia in open-heart surgery: A review. Can J Anaesth 1980;27:381-8.
5. Valooran GJ, Nair SK, Chandrasekharan K, Simon R, Dominic C. del Nido cardioplegia in adult cardiac surgery—Scopes and concerns. Perfusion 2016;31:6-14.
6. Matte GS, del Nido PJ. History and use of del Nido cardioplegia solution at Boston children’s hospital. J Extra Corpor Technol 2012;44:98-103.
7. Gorgy A, Shore-Lesserson L. Del Nido cardioplegia should be used in all adults undergoing cardiac surgery: Con. J Cardiothorac Vasc Anesth 2019;33:1785-90.
8. Mishra P, Jadhav RB, Mohapatra CK, Khondekar J, Raut C, Ammannaya GK, et al. Comparison of del Nido cardioplegia and St. Thomas hospital solution – Two types of cardioplegia in adult cardiac surgery. Kardiochir Torakochirurgia Pol 2016;13:295-9.
9. Engorenka MC, Habib RH, Zachariais A, Schwann TA, Riordan CJ, Durham SJ, et al. The association of elevated creatine kinase-myocardial band on mortality after coronary artery bypass graft surgery is time and magnitude limited. Eur J Cardiothorac Surg 2005;28:114-9.
10. Habertheuer A, Kocher A, Lauerer G, Andreas M, Szeto WY, Petzelbauer P, et al. Cardioprotection: A Review of Current Practice in Global Ischemia and Future Translational Perspective. Hindawi Publishing Corporation BioMed Res Int 2014. Article ID 325725.
11. Spellman J. Pro: In favor of more generalized use of del Nido cardioplegia in adult patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2019;33:1785-90.
12. Sadeghi S, Austin N, Totonchi Z, Bakhshandeh H, Hadavand N, Ghavidel AA. Impact of procaine hydrochloride versus lidocaine in cardioplegic solution on reperfusion arrhythmia during coronary artery bypass graft surgery. Multidiscip Cardiovasc Ann 2018;9:e67749.
13. Guajardo Salinas GE, Nurtt R, Rodriguez-Araujo G. Del Nido cardioplegia in low risk adults undergoing first time coronary artery bypass surgery. Perfusion 2017;32:68-73.
14. Sorabella RA, Akashi H, Yerebakan H, Najjar M, Mannan A, Williams MR, et al. Myocardial protection using del nido cardioplegia solution in adult reoperative aortic valve surgery. J Card Surg 2014;29:445-9.
15. Ad N, Holmes SD, Massimiano PS, Rongione AJ, Fornarese LM, Fitzgerald D. The use of del Nido cardioplegia in adult cardiac surgery: A prospective randomized trial. J Thorac Cardiovasc Surg 2018;155:1011-8.
16. Timek T, Willekes C, Hulme O, Himelhoch B, Nadeau D, Borgman A, et al. Propensity matched analysis of del Nido cardioplegia in adult coronary artery bypass grafting: Initial experience with 100 consecutive patients. Ann Cardiothorac Surg 2016;101:2237-42.
17. Ota T, Yerebakan H, Neely RC, Mongero L, George I, Takayama H, et al. Short-term outcomes in adult cardiac surgery in the use of del Nido cardioplegia solution. Perfusion 2016;31:27-33.

18. Mick SL, Robich MP, Houghtaling PL, Gillinov AM, Soltesz EG, Johnston DR, et al. Del Nido versus buckberg cardioplegia in adult isolated valve surgery. Ann Cardiothorac Surg 2015;149:626-36.

19. Kim WK, Kim HR, Kim JB, Jung S, Choo SJ, Chung CH, et al. Del Nido cardioplegia in adult cardiac surgery: Beyond single-valve. Interact Cardiovasc Thorac Surg 2018;27:81-7.

20. Hofmann B, Kaufmann C, Stiller M, Neitzel T, Wienke A, Silber R, et al. Positive impact of retrograde autologous priming in adult patients undergoing cardiac surgery: A randomized clinical trial. J Cardiothorac Surg 2018;13:50.

21. Teman N, Delavari N, Romano M, Prager R, Yang B, Haft J. Effects of autologous priming on blood conservation after cardiac surgery. Perfusion 2014;29:333-9.

22. Sellevold OFM, Berg EM, Levang OW. Procaine is effective for minimizing postsischemic ventricular fibrillation in cardiac surgery. Anesth Analg 1995;81:932-8.

23. O’Donnell C, Wang H, Tran P, Miller S, Shuttleworth P, Boyd JH. Utilization of del Nido cardioplegia in adult coronary artery bypass grafting—a retrospective analysis. Circ J 2019;83:342-6.

24. Buel ST, Striker CW, O’Brien JE. Del Nido versus St. Thomas cardioplegia solutions: A single-center retrospective analysis of post cross-clamp defibrillation rates. J Extra Corporeal Technol 2016;48:67-70.

25. Vistarini N, Laliberte E, Beauchamp P, Bouhout I, Lamarche Y, Cartier R, et al. Del Nido cardioplegia in the setting of minimally invasive aortic valve surgery. Perfusion 2017;32:112-7.

26. Hamad R, Nguyen A, Laliberte E, Bouchard D, Lamarche Y, El-Hamamsy I, et al. Comparison of del Nido cardioplegia with blood cardioplegia in adult combined surgery. Innovations (Phila) 2017;12:556-62.

27. Yerebakan H, Sorabella RA, Najjar M, Castillero E, Mongero L, Beck J, et al. Del Nido cardioplegia can be safely administered in high-risk coronary artery bypass grafting surgery after acute myocardial infarction: A propensity matched comparison. J Cardiothorac Surg 2014;9:141.

28. Gundry SR, Sequeira A, Coughlin TR, McLaughlin JS. Postoperative conduction disturbances: A comparison of blood and crystalloid cardioplegia. Ann Cardiothorac Surg 1989;47:384-90.